|
|
Article: Pharmacology Update: Levalbuterol Tartrate Inhalation Aerosol (Xopenex HFA[TM]).
- Article from:
- Internal Medicine Alert
- Article date:
- January 29, 2006
CopyrightCOPYRIGHT 2006 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Pharmacology Update
Levalbuterol Tartrate Inhalation Aerosol (Xopenex HFA?)
By William T. Elliott, MD, FACP, and James Chan, PhD, PharmD Dr. Elliott is Chair, Formulary Committee, Northern California Kaiser Permanente; Assistant Clinical Professor of Medicine, University of California, San Francisco; Dr. Chan is Pharmacy Quality and Outcomes Manager, Kaiser Permanente, Oakland, CA. Drs. Chan and Elliott report no financial relationships to this field of study.
The FDA has approved a cfc-free levalbuterol aerosol inhaler for the treatment of asthma. Levalbuterol is the active isomer of albuterol and has been available in a nebulized solution for ...